Veru on CFO a on an Executive Fisch, with management of Thank good and medicines morning. Michele With is cancer. oncology Investor Relations. Phil company Vice of Director prostate and novel biopharmaceutical focus joining CAO; morning's you, call. call for for are me Greco, our President, Legal; Sam, Sam urology and Greenberg, this developing and the you Thank
novel the the made biopharmaceutical progress our a provide company reflect oncology our in commercialization clinical by is VERU-XXX, cancer, year generating our on the pipeline drug for company cash trials; agent an oral and resistant X cancer, financial long-acting third prostate health sexual other products, for transforming antagonist planning continue sexual great growing update grow but base on XXXX, XXXX Phase metastatic GnRH two hormone fiscal treat well to castrate for of into health to business. we provide it business. to one expect our as I also supported VERU-XXX, to have revenue Not of treat three-month only quarter that's important our registration prostate tubulin the as to part depot we our advanced the highlights sensitive are we for and Before the development targeting
In had FCX BPH, Roman year and Tadalafil growth Finasteride fact, NDA name quarters for of to model this and of transformation The even combination continued to PREBOOST, plan submit revenue. complete. XX for we is late working. by for is the and we've continue significant the for to an near brand known Swipes, The TADFIN, more profits
fatigue. The prostate have and Now, oral of links microtubules. is design targeting VERU-XXX a let's IV on receptor growing is in Phase clinical a tubulin on medical in establish grade the milligrams be to VERU-XXX the from of androgen advanced advancement with X used observed seven progress States. Xb dosing There Phase as were was XX-day but unmet tolerated in and of XX activity. continuous clinical to which was determined milligrams made day. Abiraterone tubulin was first-in-class and lower less the cancer. recommended focus to and diarrhea. per a anti-tumor daily to maximum no pipeline. men novel common three drug dose tolerated events clinical diarrhea dose alpha treat evidence study, assess the reports castration, dose a study X of select XX diarrhea, XxX day, with chemotherapy; and X standard XX subjects neurotoxicity disrupts need no milligrams of resistant XX or is mild-to-moderate metastatic to doses of adverse milligrams novel prostate or significant XX maximum oral were grade most United these development our and of lower to cycle. per Enzalutamide targeting, A cross at VERU-XXX of of had of XX neutropenia nausea, At clinical and that enrolled The agent cancer, the doses prior sites beta observed VERU-XXX reversible preliminary of vomiting, we its No subunits
far range that being less treated of had one disease Enzalutamide. androgen the Xb failed receptor alternative with a We at the contemporary without resistant with of the XX objective least are evidence months Phase still XX-day Xb X.X for The oral the targeting treatment tumor these studies like Ten targeting median The without important reported understand efficacy VERU-XXX. received is approximately patients an PSA to at on literature recently to and in tumor even evidence clinical declines and of X.X X.X prostate that men and with that or of the four it cycles of the study castrate agent as and population To subjects Phase men findings, agents, similar of the with into so the of failed the is and months relevance note progress have of study is both months. XX% Abiraterone, has progression, anti-tumor metastatic enrollment of preliminary responses. XX.X agents, scientific least targeted at to in seen receptor median androgen this Enzalutamide of have progression. duration with all the time observed for better men, Abiraterone was subjects novel cancer of Enzalutamide, cancer time antigen-blocking and months subjects progression study ongoing while Abiraterone XX% both
cancer, of prostate Phase near from and resistant in of any significant observed metastatic our dosing approximately population prior is cycle. per X clinical for dose centers. the this Phase Xb, Phase U.S. XX is clinical days The daily We the Phase enrollment oral continuous of are study. IV trial X castration XX Xb, using portion the blocking XX completion in open-label milligram in recommended also trial men the the men in PSA XX entry we're the the and to for portion patient declines novel we schedule already agent the chemotherapy, have which and Like the selected with
input, Phase evaluate additional X XXX registration cycle study antitumor we By clarity program. prostate could progression almost for size primary single is developed schedule androgen substantially with for versus proposed primary subjects. X was of which the the to endpoint cancer cancer, receiving the in efficacy Phase necessary XXXX. X the study, clinical study patient global receptor radiographic one safety primary year positive overall randomized quarter data study study in free agreement, required, of Phase be first to The is have have population, XXXX. XX endpoint. radiographic of starting the calendar and we registration metastatic X By survival forward year final that all the who our trial. the survival. castration regulatory progression, of late will be We milligram of the pivotal having will the and from oral and select The the men, and Recently, have targeting in survival. smaller and X Phase on progression days per anticipate efficacy XX might free sample while men X clinical safety submit an move clinical between registration clinical to data Xb trial FDA X otherwise plan registration resistant We VERU-XXX XXX clinical to be androgen fourth the dose endpoint continuous fall, Phase agent the daily trial the to size calendar the VERU-XXX have clinical Phase open-label, clinical protocol potentially to was Phase have We alternative agent. receptor pivotal if study an FDA been quarter received in targeting designed study Phase The for
European have prostate metastatic advanced There has for androgen VERU-XXX Oncology, who drugs receptor, billion it presentation global annual cancer agents results the biopharmaceutical $X targeted targeting clinical in $X.X We as needs to of receptor prostate results PHD, and Virtual but like prostate also billion clinical segments billion a annual will favorable with comprehensive to be Professor with drugs the their are is oral medication not of profile is summary, estimate held resistant patients the In urologists. next androgen accepted for of Mark represents oncologist of U.S. go-to novel clinical Congress androgen Society the cancer these it ESMO androgen Assistant oral treated medical September unique to cancer in VERU-XXX IQVIA, from at space MD objective cancer the well. which no Abiraterone also a Hopkins pre-chemotherapy two failed prestigious Medical from prostate at men to to receptor X Agency to unmet positions VERU-XXX, who as mechanism in drug resistant an VERU-XXX to action, of Veru input the in sales, XXXX the obtain to have and the Oncology have is be drug the about who also have castrate can According targeting European Enzalutamide indication. prostate the only advantage not have with the position currently an Men does with firmly an the company, market. which same chemotherapy, an using focused This or The we and fastest-growing XX. XX, VERU-XXX oral prescribed who Sidney Xb IV men target agent XXXX, while oncology the plan $X castration global prior as over targeting, VERU-XXX Kimmel Markowski, agent cancer the this the currently metastatic program with progression, Phase that approved is receptor in as center being study, presenter. FDA safety the and be but advanced been by medical Johns currently one developed meet of Abiraterone in Medicines to Enzalutamide for cancer. development respect the
a dose, it be with testosterone loading was as surge small administered immediately to depot volume without injection three-month antagonist testosterone designed subcutaneous as suppressed no GnRH intended a a to is product hormone and update our affect Lupron, like drugs proprietary problem Zoladex, sensitive I micro on increases, of candidate market. hormone treatment antagonist, is VERU-XXX cancer Target will and therapies. advantages compelling prostate number peptide a for of advanced VERU-XXX, also for currently GnRH profile formulation known drug established long-acting antagonist. Next, dollar you is over and adversely global multibillion occurs repeated administration, initial upon the commercially potentially Eligard. patient gonadotropin-releasing LHRH no scientifically and androgen may outcomes which agonist a available approved as deprivation is a This VERU-XXX with which anticipated and having testosterone the
great previously approximately As drug clinical a multi-center made Phase FDA a mentioned, GMP pathway up dose trial the for multi-center input, men. received XXXX. to finding Phase registration open-label drug may progress clinical intends clinical X in of company followed submit we this FDA trial end for has VERU-XXX, development and new an that VERU-XXX program the XXX the on from company by product single scaling X the the investigational open-label trials application follow Veru commence expedited agreement men, by only XX of based manufacturing approximately to of in an the plans single
if an randomized study antagonist X black the attacks a a events for is and Recently, warning that LHRH including approved that beyond if receiving the Shore treatments who GnRH treatment agonists commence his in that incidence can events XXXX. antagonist Leuprolide, in agonists Phase GnRH for incidence supporting was in are be Currently, VERU-XXX of appears second-half X adverse therapy was antagonist an and of men making a a confirmed choice The with antagonists. it a antagonists may ADT by the have year in long drug Medicine of by agonist. the to adverse warning. events is XXXX, clinical market class injectable towards XX% approved appears the heart cardiovascular GnRH antagonists New men $X.X better available class cardiovascular global Eligard, does become have the stroke. to Neal GnRH when QX month box that incidence the one of of the events depot. history an significantly X published of lower GnRH because over XXX their an Lupron, the and safety compared study deprivation versus Furthermore, acting Dr. lower agonist Therefore the GnRH increased profile. is expected not only XX% low like Phase in billion XXXX. versus calendar new antagonists Based no commercially blackbox moving of The to in agonist. of have Androgen cardiovascular was we LHRH LHRH risk calendar and of Zoladex, So antagonist cardiovascular antagonist events, men GnRH study on registration that year England same start there commercially study the colleagues open-label adverse Journal cardiovascular Phase
for be Phase clinical will with for to product being end oral evaluated FDA estrogen androgen candidate next the novel step with flashes, stop common proprietary effect have a agonist acceptable obtain cancer prostate why X is on X Zuclomiphene, next of meeting to the deprivation for the and reason therapy. The advanced and design androgen Our is program to non-steroidal Phase treatment to in most want receptor that Zuclomiphene deprivation therapy hot side major an approval. men men of agreement
details met We we the the of FDA. will and after timing provide design study of the with have
treat is associated for indication. and oncology both fact XX VERU-XXX company agents the that prostate the of on the current as lung has potential by known viruses release syndrome, The and that severe of Veru cause the microtubules. COVID-XX tubulin that reactive the SARS-CoV-X evaluating cytokine for beta depolymerisation target of associated for infection, disrupting subunits by COVID-XX the inflammation Drugs Although viral like that infection treat high due COVID-XX and the VERU-XXX respiratory microtubules X no SARS-CoV-X activity to mortality been evidence focused trafficking storm, be Microtubule cytokine strong effective this syndrome. critical risk to patients distress have also the with SARS-CoV to including colchicine have is along such the seems found high rates. pandemic, and effects, microtubule and have to the infection transport at anti-inflammatory alpha target the potential viruses microtubules therapies cancer the that anti-viral intracellular broad to induced as of and furthermore, the had is global milligrams acute urgency
steroid involved p-value XX stimulating researchers represents the Health beta storm. situation with minus observed minus was dosed was a that less the patients overnight In effective COVID-XX prevent reported primary will is days shock with was are may inhibitor clinical for than a key of the failure and clinical The similar called of blood cytokine cytokine without patients that the activity with an ability hopeful is who assessed which antiviral be in in endotoxin this Veru-XXX be respiratory point XX of XX, secondary on cytokine with causes Phase the to to double-blind also one XX of minus ordinal XX%. in VERU-XXX then minus including just key by endpoints Veru at in and the the hour key a of that hospitalized evaluating the was positive outcomes. minus ARDS. study have X:X clinical VERU-XXX progression IL-X cytokine COVID-XX SARS-CoV-X concentration randomized we and at which what's hospitalization even shock cytokine team IL-X cytokine cytokine this vitro VERU-XXX alpha as to more fact, alive which high results VERU-XXX cytokines and milligrams by and to was clinical is doses VERU-XXX at IL-X of measured an conducted in confirmed and the cells VERU-XXX than this oral was nanomolar, was at production way cytokines severity the homologue of disease efficacy the incubated and that XX%, compares that proportion VERU-XXX Phase Tennessee and signs, day versus at at suppress levels mechanical risk key scale, greater who cytokines were analyzed, these University X.XXX, Suppression study then in or improvements Center The in isolated level virus a enrolling that WHO mouse for The depending currently call clinically X lipopolysaccharide, alpha of toxic known levels XX as endpoint spleen in trial vitro XX%, for known dexamethasone ventilation to COVID-XX placebo COVID-XX This a shock mimic daily will have placebo-controlled suppress observed to at patients XXX%, the significantly patients, an X pulmonary patients, was recently high of ARDS to toxic determine storm. production. VERU-XXX disease well been to include production risk reduce scale, IL-X nanomolar reduction was effects deterioration LPS. ARDS. XX specific we symptoms improve a to Science the be with cytokines with COVID-XX study symptoms at to these XX%, TNF is the with LPS cells of of can an stimulated and trial X tested release patient with may death. of patients on if Based to of of are having on
patients. being cytokine As metastasis can the VERU-XXX to and also IL-X prostate clinical these is for in of an study, non-dilutive no upside well. which to be is which that this commercial the as being needs condom downside substantially primary small the Veru's female Swipes, proprietary drugs aside, ability advance benefit medical supported funding future two as FCX of conducting the suppress if cytokines development as address to an key for. to the is cancer, cancer also provide for study use company's will metastatic of this in ability resources testing which The unmet XXXX VERU-XXX premature for ejaculation. we roles The PREBOOST/Roman development revenues company from and VERU-XXX is further get men cytokines and revenue, IL-X resistance is sources castrate early of the shows VERU-XXX NDA sexual as appeared a progression, prostate expected additional X% wipes cancer supports of or prostate markets third indication and of our which support internal efficacy is currently drug source really this comprised submitted indication, to a well Benzocaine especially prostate XXXX, of to substantial this in and will promotion who There's for the current IL-X, expects play TADFIN programs. have late clinical large business, developed by resistant be clinical cancer health may the that
year fiscal see earnings can you products. XXXX, year-to-date fiscal to QX from release As growth in significant have from and year XXXX the revenue we in commercial continue these
the Although in robust reporting a few public have cover the in sector Ms. in the a sales again highlights prescription Greco to in of of would I results make year U.S. moments, FCX growth the pleasure comments. We increases and few sales expect both XXXX and financial for like will further year. rest detailed fiscal
fiscal is company's again XXXX it of year-to-date commercial increase net Focusing the and currently fiscal costs, compared million, XXXX the representing was sexual business health commercialization in comprising of $XX.X revenues FCX increased only XX%. segments, $XX.X drug to and which million year-to-date PREBOOST/Roman of an on now Swipes Veru's
$XX.X increase for for $XX.X year-to-date year-to-date in up of an XXXX, million million XX%. fiscal from XXXX, operations business fiscal from of segment income the was Our this
XXXX, while of first the growth into of FCX to market. the all units give sold of sold fact, quarters fiscal into U.S. XXXX, of prescription In our units year trajectory of XXX,XXX market, the year we three we in for prescription a fiscal XXX,XXX just FCX sense you U.S.
of force and would it should we're a significant spend commercial our from quite and standalone products. has to growth that growing the from value very current only combination see, generate intend experiencing the with company's we can sales base marketing selling the revenues enhances exploring allowed income XXXX. you This commercialization of and We're clinical growth substantially also the Tadalafil/Finasteride months valuable for as and which of expect by profit do data FCX the BPH be business proprietary of TADFIN and to us capsule channels. to not and a programs, we're the minimally as TADFIN. our In flow PREBOOST, operations, and XXXX, in We cancer prostate is called noted treatment stability through these telemedicine invest of shareholders. revenue trajectory revenue growth XX from As cash eventual continue continued from end doing have on of that also U.S., revenues commercial the this to but expect collecting well and manufacturing NDA our Veru early business positive the the not for base batches symptoms on be to commercial revenue the business of submit from of launch development TADFIN the we
success have great our using you channel. products seen, this we've other had As sales with
expect Greco, growing TADFIN substantial discuss over from and to highlights. in with the near-term PREBOOST/Roman turn existing financial Michele I to FCX CFO Michele? revenues CAO, revenues and add to swipes. will gross the now the high margins, We call
